Celldex Therapeutics, Inc. - 8-K Filing
Celldex Therapeutics reported first-quarter 2026 financial results, including a net loss of $78.7 million ($1.18 per share), driven by $73.0 million in R&D expenses and $11.4 million in G&A expenses. The company raised $345 million in gross proceeds from a follow-on public offering in April 2026 and completed enrollment six months ahead of schedule in its Phase 3 barzolvolimab trials for chronic spontaneous urticaria, with topline data expected in Q4 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CLDX